Few More Lessons Learnt from Covid-19: Health Technology Assessment (HTA) Perspective

Authors

DOI:

https://doi.org/10.55489/njcm.130820222103

Keywords:

Covid-19, Health Technology assessment

Abstract

Covid-19 is an unprecedented situation to all of us leading to dilemma in the management across the globe. Health Technology assessment (HTA) is an evidence-based multidisciplinary policy analysis comparing properties and effects of new and existing health technologies (surgical or interventional procedure, drugs, vaccines etc) with current standard using unbiased, reproducible systematic scientific methods. In other words, it is a form of policy research that examines short- and long-term consequences of the application of existing and upcoming healthcare technology. HTA can be very helpful in policy and decision-making, particularly for developing and emerging countries. It is high time to popularize the concept of HTA across the globe so that efficient use and equitable distribution of various technologies, medications and resources can be ensured and we take further concrete step towards India’s Global commitment of Universal Health Coverage (UHC).

References

World Health Organization. 2020. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. (Accessed 11 March 2020) [Google Scholar]

Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020:4539-47.

Hançer AT, Yilmaz P, Yilmaz M. New Coronavirus (2019-nCoV/COVID-19) and Vitamin C. Türkiye Klinikleri. Tip Bilimleri Dergisi. 2020 Mar 1;40(2):260-4. Doi: https://doi.org/10.5336/medsci.2020-76024 DOI: https://doi.org/10.5336/medsci.2020-76024

Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer?. The Lancet Diabetes & Endocrinology. 2020 Sep 1;8(9):735-6. Doi: https://doi.org/10.1016/S2213-8587(20)30268-0 DOI: https://doi.org/10.1016/S2213-8587(20)30268-0

Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID‐19. Cochrane Database of Systematic Reviews. 2021(7). Doi: https://doi.org/10.1002/14651858.CD015017 PMCid:PMC8078284 DOI: https://doi.org/10.1002/14651858.CD015017

Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. The Lancet Infectious Diseases. 2021 Jan 1;21(1):20-1. Doi: https://doi.org/10.1016/S1473-3099(20)30911-7 DOI: https://doi.org/10.1016/S1473-3099(20)30911-7

Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment. Journal of the International AIDS Society. 2020 Apr;23(4):e25489. Doi: https://doi.org/10.1002/jia2.25489 DOI: https://doi.org/10.1002/jia2.25489

Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X. The anti-influenza virus drug, arbidol is an efficient inhibi-tor of SARS-CoV-2 in vitro. Cell discovery. 2020 May 2;6(1):1-5. Doi: https://doi.org/10.1038/s41421-020-0169-8 PMid:32373347 PMCid:PMC7195821 DOI: https://doi.org/10.1038/s41421-020-0169-8

Nagoba B, Gavkare A, Jamadar N, Mumbre S, Selkar S. Positive aspects, negative aspects and limitations of plasma therapy with spe-cial reference to COVID-19. Journal of infection and public health. 2020 Dec 1;13(12):1818-22. Doi: https://doi.org/10.1016/j.jiph.2020.08.011 PMid:32900666 PMCid:PMC7462592 DOI: https://doi.org/10.1016/j.jiph.2020.08.011

Khan IA, Bashar MA, Tiwari HC. Attitude, perceptions and willingness to receive COVID-19 vaccine and their associated factors among general population of Uttar Pradesh, Northern India.

Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-effectiveness analysis alongside clinical trials II-an ISPOR Good Research Practices Task Force report. Value in Health. 2015 Mar 1;18(2):161-72. Doi: https://doi.org/10.1016/j.jval.2015.02.001 PMid:25773551 DOI: https://doi.org/10.1016/j.jval.2015.02.001

Department of Health Research, Ministry of Health and Family Welfare, Government of India. Available from: https:// www.dhr.gov.in/about-mtab, accessed on May 31, 2018.

Jain S, Rajshekar K, Sohail A, Gauba VK. Department of health research-health technology assessment (DHR-HTA) database: national prospective register of studies under HTAIn. The Indian Journal of Medical Research. 2018 Sep;148(3):258. Doi: https://doi.org/10.4103/ijmr.IJMR_1613_18 PMid:30425215 PMCid:PMC6251258 DOI: https://doi.org/10.4103/ijmr.IJMR_1613_18

Prinja S, Downey LE, Gauba VK, Swaminathan S. Health technology assessment for policy making in India: current scenario and way forward. PharmacoEconomics-Open. 2018 Mar;2(1):1-3. Doi: https://doi.org/10.1007/s41669-017-0037-0 PMid:29464668 PMCid:PMC5820238 DOI: https://doi.org/10.1007/s41669-017-0037-0

Downloads

Published

2022-08-31

How to Cite

1.
Khan IA, Malik N. Few More Lessons Learnt from Covid-19: Health Technology Assessment (HTA) Perspective. Natl J Community Med [Internet]. 2022 Aug. 31 [cited 2022 Sep. 30];13(08):576-7. Available from: https://www.njcmindia.com/index.php/file/article/view/2103

Issue

Section

Short Communication